Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Jayne

Showing results (271-280 of 341) with videos related to

Pageof 35
Sort By:
RMD Open|October 6, 2025
Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trialPatrick G Gavin, Erik L Allman, David Jayne, et al.
Rheumatology (Oxford, England)|January 29, 2019
A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitisRuth J Pepper, Stephen P McAdoo, Sarah M Moran, et al.
Rheumatology (Oxford, England)|March 22, 2024
Neuropsychiatric symptoms in systemic lupus erythematosus: mixed methods analysis of patient-derived attributional evidence in the international INSPIRE projectMelanie Sloan, Thomas A Pollak, Efthalia Massou, et al.
Rheumatology (Oxford, England)|December 18, 2023
Attribution of neuropsychiatric symptoms and prioritization of evidence in the diagnosis of neuropsychiatric lupus: mixed methods analysis of patient and clinician perspectives from the international INSPIRE studyMelanie Sloan, Laura Andreoli, Michael S Zandi, et al.
The New England Journal of Medicine|July 4, 2003
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodiesDavid Jayne, Niels Rasmussen, Konrad Andrassy, et al.
The New England Journal of Medicine|May 18, 2017
Mepolizumab or Placebo for Eosinophilic Granulomatosis with PolyangiitisMichael E Wechsler, Praveen Akuthota, David Jayne, et al.
Annals of the Rheumatic Diseases|January 7, 2019
Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trialRachel B Jones, Thomas F Hiemstra, Jose Ballarin, et al.
Arthritis Care & Research|April 1, 2011
A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitisRavi Suppiah, Andrew Judge, Rajbir Batra, et al.
The Journal of Rheumatology|June 7, 2007
The future of damage assessment in vasculitisPhilip Seo, Raashid A Luqmani, Oliver Flossmann, et al.
Nature Reviews. Rheumatology|October 16, 2025
Challenges in the diagnosis, classification and prognosis of ANCA-associated vasculitisMarta Casal Moura, Peter A Merkel, David Jayne, et al.
Pageof 35

Showing results (271-280 of 341) with videos related to

Sort By:
Pageof 35
RMD Open|October 6, 2025
Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trialPatrick G Gavin, Erik L Allman, David Jayne, et al.
Rheumatology (Oxford, England)|January 29, 2019
A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitisRuth J Pepper, Stephen P McAdoo, Sarah M Moran, et al.
Rheumatology (Oxford, England)|March 22, 2024
Neuropsychiatric symptoms in systemic lupus erythematosus: mixed methods analysis of patient-derived attributional evidence in the international INSPIRE projectMelanie Sloan, Thomas A Pollak, Efthalia Massou, et al.
Rheumatology (Oxford, England)|December 18, 2023
Attribution of neuropsychiatric symptoms and prioritization of evidence in the diagnosis of neuropsychiatric lupus: mixed methods analysis of patient and clinician perspectives from the international INSPIRE studyMelanie Sloan, Laura Andreoli, Michael S Zandi, et al.
The New England Journal of Medicine|July 4, 2003
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodiesDavid Jayne, Niels Rasmussen, Konrad Andrassy, et al.
The New England Journal of Medicine|May 18, 2017
Mepolizumab or Placebo for Eosinophilic Granulomatosis with PolyangiitisMichael E Wechsler, Praveen Akuthota, David Jayne, et al.
Annals of the Rheumatic Diseases|January 7, 2019
Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trialRachel B Jones, Thomas F Hiemstra, Jose Ballarin, et al.
Arthritis Care & Research|April 1, 2011
A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitisRavi Suppiah, Andrew Judge, Rajbir Batra, et al.
The Journal of Rheumatology|June 7, 2007
The future of damage assessment in vasculitisPhilip Seo, Raashid A Luqmani, Oliver Flossmann, et al.
Nature Reviews. Rheumatology|October 16, 2025
Challenges in the diagnosis, classification and prognosis of ANCA-associated vasculitisMarta Casal Moura, Peter A Merkel, David Jayne, et al.
Pageof 35